OBJECTIVE: To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease. DESIGN: Systematic review and meta-analysis. DATA SOURCE: Electronic literature search without language restrictions of four databases and hand search of bibliographies for other relevant articles. REVIEW METHODS: Inclusion criteria included a test for platelet responsiveness and clinical outcomes. Aspirin resistance was assessed, using a variety of platelet function assays. RESULTS: 20 studies totalling 2930 patients with cardiovascular disease were identified. Most studies used aspirin regimens, ranging from 75-325 mg daily, and six studies included adjunct antiplatelet therapy. Compliance was confirmed directly in 14 studies and by telephone or interviews in three. Information was insufficient to assess compliance in three studies. Overall, 810 patients (28%) were classified as aspirin resistant. A cardiovascular related event occurred in 41% of patients (odds ratio 3.85, 95% confidence interval 3.08 to 4.80), death in 5.7% (5.99, 2.28 to 15.72), and an acute coronary syndrome in 39.4% (4.06, 2.96 to 5.56). Aspirin resistant patients did not benefit from other antiplatelet treatment. CONCLUSION: Patients who are resistant to aspirin are at a greater risk of clinically important cardiovascular morbidity long term than patients who are sensitive to aspirin.
OBJECTIVE: To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease. DESIGN: Systematic review and meta-analysis. DATA SOURCE: Electronic literature search without language restrictions of four databases and hand search of bibliographies for other relevant articles. REVIEW METHODS: Inclusion criteria included a test for platelet responsiveness and clinical outcomes. Aspirin resistance was assessed, using a variety of platelet function assays. RESULTS: 20 studies totalling 2930 patients with cardiovascular disease were identified. Most studies used aspirin regimens, ranging from 75-325 mg daily, and six studies included adjunct antiplatelet therapy. Compliance was confirmed directly in 14 studies and by telephone or interviews in three. Information was insufficient to assess compliance in three studies. Overall, 810 patients (28%) were classified as aspirin resistant. A cardiovascular related event occurred in 41% of patients (odds ratio 3.85, 95% confidence interval 3.08 to 4.80), death in 5.7% (5.99, 2.28 to 15.72), and an acute coronary syndrome in 39.4% (4.06, 2.96 to 5.56). Aspirin resistant patients did not benefit from other antiplatelet treatment. CONCLUSION:Patients who are resistant to aspirin are at a greater risk of clinically important cardiovascular morbidity long term than patients who are sensitive to aspirin.
Authors: Marcel M C Hovens; Jaapjan D Snoep; Jeroen C J Eikenboom; Johanna G van der Bom; Bart J A Mertens; Menno V Huisman Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; Menno V Huisman Journal: Arch Intern Med Date: 2007 Aug 13-27
Authors: James P Smith; Elias V Haddad; Mary B Taylor; Denise Oram; Dana Blakemore; Qingxia Chen; Olivier Boutaud; John A Oates Journal: Hypertension Date: 2012-02-06 Impact factor: 10.190
Authors: Jan Hartinger; Robert Novotny; Jana Bilkova; Tomas Kvasnicka; Petr Mitas; Martin Sima; Jaroslav Hlubocky; Jan Kvasnicka; Ondrej Slanar; Jaroslav Lindner Journal: Med Princ Pract Date: 2018-05-13 Impact factor: 1.927
Authors: Ali R Keramati; Lisa R Yanek; Kruthika Iyer; Margaret A Taub; Ingo Ruczinski; Diane M Becker; Lewis C Becker; Nauder Faraday; Rasika A Mathias Journal: Platelets Date: 2018-03-19 Impact factor: 3.862